论文部分内容阅读
目的 :评估重组人血小板生成素 (rhTPO)治疗特发性和化疗后血小板减少的临床安全性和有效性 .方法 :①病例分组 :4例非霍奇金淋巴瘤 (NHL)患者入选随机交叉对照组 ,6例巩固治疗期急性白血病患者入选非随机自身对照组 ;难治性血小板减少性紫癜 (ITP)组入选 9例患者 ;②用药方法 :rhTPO 1 μg/kg ,皮下注射 ,每日 1次 ,疗程 1 4d ;③统计分析 :病例资料采用SPSS软件统计分析 .结果 :①血液肿瘤组 :试验组rhTPO治疗后血小板数均值、最高值皆大于对照 ,两周期血小板数用药前后差值相差显著 (P <0 .0 5 ) ,试验组血小板数低于 5 0× 1 0 9/L的持续日数、恢复至 75× 1 0 9/L和 1 0 0× 1 0 9/L以上需要日数均有不同程度缩短 ;②难治性ITP组 :rhTPO治疗后患者血小板数均值渐升高 ,至 1 7d达 1 0 1× 1 0 9/L ;用药前后血小板差值为 85 .6 7× 1 0 9/L ,其中血小板数达 30× 1 0 9/L ,5 0× 1 0 9/L及 1 0 0× 1 0 9/L所需日数分别为 9.89,1 3.5 6及 1 9.78d .结论 :rhTPO对部分难治性ITP及血液肿瘤化疗所致的血小板减少有一定疗效 ,且无明显毒副作用
Objective: To evaluate the clinical safety and efficacy of recombinant human thrombopoietin (rhTPO) in the treatment of idiopathic and post-chemotherapy thrombocytopenia.Methods: ①Patients were divided into four groups: non-Hodgkin’s lymphoma (NHL) Group, 6 cases of consolidation treatment of acute leukemia were enrolled in the non-random self-control group; refractory thrombocytopenic purpura (ITP) group of 9 patients were selected; ② medication: rhTPO 1 μg / kg, subcutaneously once daily , And the course of treatment was 14 days.③Statistical analysis: The case data were analyzed by SPSS software.Results: ①The hematological tumor group: The mean and maximum values of platelets in the experimental group after rhTPO treatment were both greater than those in the control group, with significant difference between before and after the two- P <0.05). The number of days with platelets less than 5 0 × 109 / L in the experimental group returned to 75 × 109 / L and 100 × 109 / L (P <0.05) .Conclusion: In the refractory ITP group, the average number of platelets in patients with rhTPO gradually increased to 1101 × 109 / L on day 17 and 85.66 × 109 / L, in which the number of platelets up to 30 × 109 / L, 50 × 109 / L and 100 × 10 9 / L, respectively, the number of days were 9.89,1 3.56 and 1 9.78d.Conclusion: rhTPO on some of the refractory ITP and hematologic chemotherapy-induced thrombocytopenia have a certain effect, and no significant side effects